Not applicableStudy completedNCT03315260What this trial is testingTreatment Satisfaction With Ra-223 in JapanWho this might be right forProstatic Neoplasms Bayer 85
Testing effectiveness (Phase 2)Ended earlyNCT03531827What this trial is testingCombining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide TreatmentWho this might be right forMetastatic Castration Resistant Prostate CancerProstate Neoplasms National Cancer Institute (NCI) 4
Early research (Phase 1)Looking for participantsNCT06067841What this trial is testingAssess BMS-986460 in Participants With Metastatic Castration-resistant Prostate CancerWho this might be right forMetastatic Castration-resistant Prostate Cancer Bristol-Myers Squibb 140
Early research (Phase 1)Study completedNCT00644488What this trial is testingA Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate CancerWho this might be right forProstate Cancer Bristol-Myers Squibb 7
Testing effectiveness (Phase 2)Looking for participantsNCT07363486What this trial is testingSequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate CancerWho this might be right forProstate Cancer First Affiliated Hospital of Fujian Medical University 9
Early research (Phase 1)Study completedNCT02833883What this trial is testingUse of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate CancerWho this might be right forProstate CancerCastration Resistant Prostate Cancer Memorial Sloan Kettering Cancer Center 40
Large-scale testing (Phase 3)Not Yet RecruitingNCT07802704What this trial is testingRisvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)Who this might be right forNeoplasms, Prostate GlaxoSmithKline 684
Testing effectiveness (Phase 2)Study completedNCT01477749What this trial is testingSipuleucel-T Manufacturing Demonstration StudyWho this might be right forCancer of ProstateCancer of the ProstateNeoplasms, Prostate+4 more Dendreon 47
Early research (Phase 1)Ended earlyNCT00848601What this trial is testingSafety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's LymphomaWho this might be right forProstate CancerNon-Hodgkins Lymphoma Astex Pharmaceuticals, Inc. 14
Early research (Phase 1)Study completedNCT01574937What this trial is testingXL-184+Abiraterone in Post-Chemo CRPCWho this might be right forProstate Cancer Dana-Farber Cancer Institute 27
Early research (Phase 1)Study completedNCT02625857What this trial is testingSafety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate CancerWho this might be right forProstatic Neoplasms, Castration-Resistant Janssen Research & Development, LLC 26
Early research (Phase 1)Looking for participantsNCT07493512What this trial is testingTrial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate CancerWho this might be right forMetastatic Castration-resistant Prostate Cancer (mCRPC) Amgen 40
Testing effectiveness (Phase 2)Looking for participantsNCT07288359What this trial is testingStudy of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsWho this might be right forAdvanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer Novartis Pharmaceuticals 205
Testing effectiveness (Phase 2)Study completedNCT00020254What this trial is testingVaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate CancerWho this might be right forProstate Cancer National Cancer Institute (NCI)
Early research (Phase 1)Study completedNCT01017939What this trial is testingA Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate CancerWho this might be right forProstate Neoplasms Janssen Research & Development, LLC 34
Early research (Phase 1)Study completedNCT02730975What this trial is testingPharmacokinetic Food-effect Study of Abiraterone Acetate (AA) in Castration Resistant Prostate CancerWho this might be right forProstate Cancer Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 42
Early research (Phase 1)Looking for participantsNCT06879041What this trial is testingA Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate CancerWho this might be right forMetastatic Castration-Resistant Prostate Cancer AstraZeneca 136
Large-scale testing (Phase 3)Looking for participantsNCT07164443What this trial is testingPasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)Who this might be right forMetastatic Castration-resistant Prostatic Neoplasms Janssen Research & Development, LLC 1,203
Testing effectiveness (Phase 2)Study completedNCT01576172What this trial is testingAbiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate CancerWho this might be right forCastration-Resistant Prostate CarcinomaRecurrent Prostate CarcinomaStage IV Prostate Cancer AJCC v7 National Cancer Institute (NCI) 159
Not applicableEnded earlyNCT01076751What this trial is testingObservational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) PatientsWho this might be right forProstatic Neoplasms Sanofi 82